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The propensity of complement to damage self is
controlled by expression of regulatory proteins. Recent
results demonstrate that deleting just one of these
regulators in mice causes complement to attack and
destroy the embryo. These findings may have relevance
to human pregnancy.
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The complement system, a major component of innate
immunity, comprises a group of 15 plasma proteins that
combine in a targeted proteolytic cascade to kill pathogens
[1]. Complement can kill by directly lysing some
pathogens, notably several clinically relevant strains of bac-
teria. Of greater importance, however, is its role in attract-
ing, targeting and priming phagocytic cells for clearance of
pathogens, and in marking these pathogens for destruction.
The third component, C3, lies at the heart of the comple-
ment system, acting as a pivot to link the recognition and
effector arms of the complement cascade. C3 constantly
undergoes low-level spontaneous activation — ‘tickover’ —
ensuring immediate activation on the surface of pathogens.
Tickover activation occurring in vivo presents a serious
threat to host cells which, given the potential for rapid
amplification within the complement cascade, must find
ways to guard themselves against the consequences of
complement attack on their surfaces (Figure 1). Several
membrane proteins have evolved to provide host cells
with the protection they need to control the body’s own
complement, hence preventing damage to self [2]. In
humans, a group of three cell membrane proteins perform
this complement regulatory function: decay accelerating
factor (DAF, or CD55) and membrane cofactor protein
(MCP, or CD46) both act early in the complement cascade
to control C3 activation, while CD59 acts later in the
cascade to prevent formation of the lytic lesion generated
by the membrane attack complex [3]. 
Rats and mice produce all three of the membrane
complement regulators described in humans, albeit with
quite different patterns of distribution. They also produce
an additional, broadly distributed complement regulator
not found in other species, known as Crry [3]. Crry is
structurally similar to MCP and DAF, and has similar
complement inhibitory activities. It is clear from experi-
ments of Okada and co-workers [4] that Crry is a key com-
plement regulator in rats: systemic blockade of Crry using
F(ab) fragments of a blocking monoclonal antibody caused
spontaneous complement activation and a severe shock
syndrome. Similarly, injection of anti-Crry antibody frag-
ments into skin caused local activation of complement and
inflammation [5]. 
Like rat Crry, mouse Crry is a broadly distributed and
powerful inhibitor of complement in vitro [6]. But its
functional relevance in vivo has not been examined. The
acid test of the in vivo relevance of a complement regula-
tor is to remove it and then to see what happens. This is
essentially what was done in the antibody blocking experi-
ments described above, but another and perhaps more
effective way to do this is by gene deletion. In mice, the
gene encoding the most abundant form of DAF — mice
have two DAF genes — has been deleted with relatively
little consequence [7]. 
When Molina and colleagues [8] undertook to delete the
gene encoding Crry in mice, it is likely that they expected a
phenotype similar to that of the DAF knockout. Instead,
they discovered that homozygous Crry–/– mice died in utero:
Crry–/– embryos did in fact survive in the expected frequen-
cies until some 9.5 days post coitus but, beyond this, survival
rapidly declined with death resulting from developmental
arrest. By contrast with wild-type embryos, Crry–/– embryos
appeared to contain C3 deposited on the placenta, indicat-
ing that complement had been activated at this site. Again
by contrast with wild-type embryos, there was a marked
invasion of inflammatory cells into the placental tissue of
Crry–/– embryos. This provided additional and compelling
evidence that, in the absence of complement regulation by
placental Crry, embryos had died as a consequence of com-
plement activation in the placenta. Deposition of antibody
and of other complement components in Crry–/– placenta
was not examined, making it impossible to state precisely
how complement was activated.
To check that spontaneous activation of complement was
indeed responsible for the loss of Crry–/– embryos, Molina
and colleagues [8] hit on the clever idea of introducing the
Crry mutation onto a C3 deficient background, by crossing
the heterozygotes with C3–/– mice [9]. This ‘rescue’
strategy was spectacularly successful. On the C3–/– back-
ground, characterised by an absence of C3 protein, Crry–/–
mice survived gestation and were born healthy. Taken
together, the data convincingly demonstrate that there is
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ongoing complement activation at the fetomaternal inter-
face which must be held in check by complement regula-
tors. Molina and colleagues [8] state that MCP is not
expressed in mouse placenta, and that DAF is expressed
only in late embryos. It therefore appears that Crry alone
protects the mouse embryo from complement attack.
So what does all this mean for human pregnancy? The
journey from conception to birth is fraught with danger. It
has been estimated that between 50 and 70% of all
conceptions fail. Although a majority of these are unrecog-
nised, some 15% of recognised pregnancies are lost and
some 1–2% of women suffer three or more consecutive
miscarriages (recurrent spontaneous abortions) [10].
Complement deposition has been described in pre-
eclampsia, a syndrome associated with placental failure
[11]. However, the contribution of innate immunity, and
specifically complement activation, to all these patholo-
gies remains largely unexplored. Despite this, all three of
the known human membrane regulators — DAF, MCP
and CD59 — have been found in abundance in the human
placenta [12–14]. On the basis of their characteristic
distribution patterns, it has already been argued that these
proteins are strategically positioned to protect the placenta
from complement activation [12,13]. 
Rare individuals deficient in DAF or CD59 have been
reported, but no MCP-deficiencies have been found
[15,16]. DAF-deficient individuals had no clear pheno-
type, and the single CD59-deficient individual had a
severe hemolytic and thrombotic syndrome resembling
paroxysmal nocturnal hemoglobinuria. On the face of it,
the fact that individuals lacking DAF or CD59 have
survived pregnancy apparently unscathed makes it
unlikely that either regulator alone is essential for fetal
survival. It is tempting to speculate that the failure to find
individuals deficient in MCP, a key regulator of the alter-
native complement pathway, might suggest an essential
role for this protein, perhaps in protecting the placenta.
On the other hand, it is equally possible that these indi-
viduals have not been found because the deficiency is
without consequence. Apart from complete deficiencies,
more subtle alterations in complement regulation within
the placenta might also contribute to placental dysfunc-
tion and miscarriage. 
Where do we go from here? As a first step, we believe it is
essential that evidence for complement activation in
association with fetal loss and placental pathology should
be sought at every opportunity, in order to establish if
complement plays a role in some cases of placental failure
and miscarriage. This needs to be done urgently because
effective strategies for inhibiting complement are now
available. Powerful systemic inhibitors of complement,
often derived from the natural membrane regulators, have
been developed for therapy of complement-mediated
disease. Of these, a soluble recombinant form of comple-
ment receptor 1 (sCR1) has been most widely used
[17,18]. The mice studied by Molina and colleagues [8]
might well have been maintained to term by the simple
strategy of inhibiting complement by administering sCR1
to the mother. It seems reasonable to propose that, in
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‘Tickover’ activation of complement and protection of the placenta.
(a) C3b is continually deposited on all plasma-exposed surfaces in the
body. On a surface that lacks natural protective factors (labelled
‘activating surface’), amplification occurs with the deposition of more
C3b and other components and release of anaphylatoxins C3a and
C5a. The anaphylatoxins attract phagocytic cells to the site where they
bind the complement-coated surface and initiate tissue destruction.
(b) Tickover activation occurs on the placental trophoblast, but
expression of complement regulators inhibits amplification. In the
mouse, the recent work of Molina and colleagues [8] shows that Crry
is crucial to this inhibition. In humans, it is likely that MCP and DAF
work together to provide the necessary control.
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humans, complement-mediated placental damage might
also be prevented by using sCR1 or similar agents [19]. 
The elegant study of Molina and colleagues [8] focuses
attention once again on the problem highlighted by Peter
Medawar almost 50 years ago: how does the fetus avoid
rejection by the mother’s immune system? The
mechanisms underlying this tolerance have intrigued
immunologists and no comprehensive explanation has yet
emerged [20,21]. Most work has focussed on adaptive
immune mechanisms — antibodies and T cells. Here we
return to the biologically older, but equally effective,
innate immune system in which complement is a major
player. Molina and colleagues’ work suggests that the
placenta is attacked by complement, but survives by
virtue of expression of a protective protein. It is likely that
a similar situation pertains in humans and, hence, that a
failure to protect against complement may contribute to
placental pathology. It will indeed be gratifying if studies
aimed at bettering our understanding of the basic aspects
of complement biology lead to the emergence of novel
approaches to the treatment of pregnancy disorders.
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